Mereo Stock Performance

MREO
 Stock
  

USD 0.96  0.07  7.87%   

The company secures a Beta (Market Risk) of 1.4608, which conveys a somewhat significant risk relative to the market. Let's try to break down what Mereo's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Mereo Biopharma will likely underperform. Even though it is essential to pay attention to Mereo Biopharma Group price patterns, it is always good to be careful when utilizing equity historical price patterns. Our philosophy towards estimating any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Mereo Biopharma exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Mereo Biopharma Group has an expected return of -0.35%. Please be advised to verify Mereo Biopharma Group value at risk, as well as the relationship between the skewness and day median price to decide if Mereo Biopharma Group performance from the past will be repeated at some point in the near future.
  
Mereo Performance
0 of 100
Over the last 90 days Mereo Biopharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in November 2022. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more

Mereo Price Channel

Quick Ratio7.66
Fifty Two Week Low0.3010
Target High Price749.18
Fifty Two Week High2.5900
Target Low Price599.34

Mereo Biopharma Relative Risk vs. Return Landscape

If you would invest  132.00  in Mereo Biopharma Group on July 7, 2022 and sell it today you would lose (36.00)  from holding Mereo Biopharma Group or give up 27.27% of portfolio value over 90 days. Mereo Biopharma Group is currently does not generate positive expected returns and assumes 5.5836% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Mereo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  
Given the investment horizon of 90 days Mereo Biopharma is expected to under-perform the market. In addition to that, the company is 4.48 times more volatile than its market benchmark. It trades about -0.06 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.05 per unit of volatility.

Mereo Biopharma Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Mereo Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mereo Biopharma Group, and traders can use it to determine the average amount a Mereo Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0635

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsMREO
Estimated Market Risk
 5.58
  actual daily
 
 48 %
of total potential
 
4848
Expected Return
 -0.35
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.06
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Mereo Biopharma is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mereo Biopharma by adding it to a well-diversified portfolio.

About Mereo Biopharma Performance

To evaluate Mereo Biopharma Group Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Mereo Biopharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Mereo Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Mereo Biopharma Group market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Mereo's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.

Things to note about Mereo Biopharma Group

Checking the ongoing alerts about Mereo Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mereo Biopharma Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Mereo Biopharma Alerts

Equity Alerts and Improvement Suggestions

Mereo Biopharma generated a negative expected return over the last 90 days
Mereo Biopharma has high historical volatility and very poor performance
Mereo Biopharma has some characteristics of a very speculative penny stock
Mereo Biopharma Group currently holds about 94.3 M in cash with (5.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81.
Over 80.0% of the company shares are owned by institutional investors
Latest headline from uk.finance.yahoo.com: Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board - Yahoo Finance UK
Additionally, see Correlation Analysis. Note that the Mereo Biopharma Group information on this page should be used as a complementary analysis to other Mereo Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Mereo Stock analysis

When running Mereo Biopharma Group price analysis, check to measure Mereo Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo Biopharma is operating at the current time. Most of Mereo Biopharma's value examination focuses on studying past and present price action to predict the probability of Mereo Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mereo Biopharma's price. Additionally, you may evaluate how the addition of Mereo Biopharma to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Is Mereo Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo Biopharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mereo Biopharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo Biopharma's market value can be influenced by many factors that don't directly affect Mereo Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Mereo Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.